Drospirenone/Estradiol

屈螺酮/雌二醇

Report date: 2022/01/14 13:23:58

Base Information

Drug NameDrospirenone/Estradiol
Drug Alias NameEstradiol/Drospirenone雌二醇/屈螺酮Angeliq安今益
ClassificationSmall molecules > Steroids
Mechanisms of ActionProgesterone receptor agonistsEstrogen receptors agonistsMineralocorticoid receptor antagonists +[4] 
TargetsAndrogen ReceptorEstrogen receptorsMineralocorticoid receptor +[4] 
Therapy Area/IndicationsVasomotor symptomVulvar and vaginal atrophyAtrophy +[5] 
Global Approved IndicationsVasomotor symptomVulvar and vaginal atrophyAtrophy +[5] 
Approved Indications in ChinaVasomotor symptomVulvar and vaginal atrophyOsteoporosis, Postmenopausal
Original Approved Country/TerritoryNetherlands
Original Approved Date2003/01/01
Country/TerritoryUnited StatesNetherlandsMainland China
CombinationsYes DrospirenoneEstradiol
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesBayer Vital GmbhBayer AGBayer Healthcare Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsVasomotor symptomVulvar and vaginal atrophyAtrophy +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeG03AAG03FA
Related LinksWikipedia